Abstract: Traumatic brain injury (TBI) is a public health problem with an undue economic burden that impacts nearly every age, ethnic, and gender group across the globe (Capizzi et al., 2020). TBIs are often sustained during a dynamic range of exposures to energetic environmental forces and as such outcomes are typically heterogeneous regarding severity and pathology (Capizzi et al., 2020). Clinically, closed head mild TBI (i.e., mTBI, concussion) is the most prevalent form of TBI with nearly 25% of individuals exhibiting symptoms that persist for greater than 3 months after the initial injury (McMahon et al., 2014). Enduring symptoms often include psychiatric complications (major depressive disorder, anxiety, and social withdrawal), sleep disturbances, fatigue, and persistent, intractable headaches (Ledreux et al., 2020). The field has identified these, and other clinically relevant symptoms and pathologies associated with various forms of brain injuries, however a comprehensive understanding of the precise molecular mechanisms driving these symptoms and their pathology is inadequate. Despite decades of research and resources allocated to identify targetable pathologies underlying the emergent psychiatric phenomena associated with TBI, no U.S. Food and Drug Administration-approved pharmacotherapies are currently available for any form of TBI. Exacerbating this issue, available pharmacotherapies for treating the aforementioned symptoms and comorbidities associated with TBI lack sufficient efficacy.